Donanemab, a monoclonal antibody designed to clear brain amyloid plaque, significantly slowed clinical progression at 76 weeks in patients with early symptomatic Alzheimer disease and amyloid and tau pathology.
Donanemab, a monoclonal antibody designed to clear brain amyloid plaque, significantly slowed clinical progression at 76 weeks in patients with early symptomatic Alzheimer disease and amyloid and tau pathology.
Elevated levels of inflammatory biomarkers were associated with increased dementia risk in a population-based cohort study published online in PLOS One.
“In this study, we found associations between higher systemic inflammation levels and...
Elevated levels of inflammatory biomarkers were associated with increased dementia risk in a population-based cohort study published online in PLOS One.
“In this study, we found associations between higher systemic inflammation levels and...
New opioid use by older adults with dementia has been associated with an 11-times higher risk within the first 2 weeks of initiating opioid use, according to a study released at the Alzheimer’s Association International Conference in...
New opioid use by older adults with dementia has been associated with an 11-times higher risk within the first 2 weeks of initiating opioid use, according to a study released at the Alzheimer’s Association International Conference in...
Non-Hispanic White people have the largest prevalence of multiple sclerosis of any racial group in the United States, followed by non-Hispanic Black individuals, according to a population-based cohort study published in JAMA Neurology.
Non-Hispanic White people have the largest prevalence of multiple sclerosis of any racial group in the United States, followed by non-Hispanic Black individuals, according to a population-based cohort study published in JAMA Neurology.
Delusions experienced by people with Alzheimer Disease are not a direct consequence of forgetting or misremembering, according to a cross-sectional study published in JAMA Psychiatry
Delusions experienced by people with Alzheimer Disease are not a direct consequence of forgetting or misremembering, according to a cross-sectional study published in JAMA Psychiatry
A novel scoring system may help predict a person’s risk of developing amyotrophic lateral sclerosis (ALS) by weighing the combined effects of common genetic variants, according to a study published online in Neurology Genetics.
“This...
A novel scoring system may help predict a person’s risk of developing amyotrophic lateral sclerosis (ALS) by weighing the combined effects of common genetic variants, according to a study published online in Neurology Genetics.
“This...
Having persistent distressing dreams in middle childhood was associated with an 85% increased risk of developing cognitive impairment or Parkinson disease by age 50 compared with never having distressing dreams.
Having persistent distressing dreams in middle childhood was associated with an 85% increased risk of developing cognitive impairment or Parkinson disease by age 50 compared with never having distressing dreams.
A new study has found physiological evidence that depression following traumatic brain injury (TBI) may be clinically distinct from traditional major depressive disorder (MDD).
A new study has found physiological evidence that depression following traumatic brain injury (TBI) may be clinically distinct from traditional major depressive disorder (MDD).
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click